Leading American cancer organizations have released updated focused guidelines for patients with early-stage breast cancer.
Sponsoring Organization: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical OncologyTarget Audience: Multidisciplinary cancer-treatment teams, including general and oncologic surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, and plastic surgeons
Background and Objective
Postmastectomy radiotherapy (PMRT) is clearly indicated for patients with very high risk for local regional failure, such as those with stage III breast cancers. However, use of PMRT is controversial for patients with earlier-stage breast cancer — particularly for those with three or fewer positive nodes — because local failure rates are much lower now than in the past. Added to this conundrum…
Reviewing Author
DisclosuresSpeaker's BureauPhysicians’ Education Resource, LLC
RoyaltiesMcGraw-Hill Professional; UpToDate, Inc.
Editorial BoardsAnnals of Surgical Oncology
Leadership Positions in Professional SocietiesAmerican Society of Breast Surgeons (Chair, Publications Committee)
DisclosuresSpeaker's BureauPhysicians’ Education Resource, LLC
RoyaltiesMcGraw-Hill Professional; UpToDate, Inc.
Editorial BoardsAnnals of Surgical Oncology
Leadership Positions in Professional SocietiesAmerican Society of Breast Surgeons (Chair, Publications Committee)